Veracyte Stock

Veracyte P/S 2024

Veracyte P/S

3.45

Ticker

VCYT

ISIN

US92337F1075

WKN

A1W7EA

As of Nov 2, 2024, Veracyte's P/S ratio stood at 3.45, a -34.54% change from the 5.27 P/S ratio recorded in the previous year.

The Veracyte P/S history

Veracyte Aktienanalyse

What does Veracyte do?

Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Veracyte's P/S Ratio

Veracyte's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Veracyte's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Veracyte's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Veracyte’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Veracyte stock

What is the price-to-earnings ratio of Veracyte?

The price-earnings ratio of Veracyte is currently 3.45.

How has the price-earnings ratio of Veracyte changed compared to last year?

The price-to-earnings ratio of Veracyte has increased by -34.54% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Veracyte high compared to other companies?

Yes, the price-to-earnings ratio of Veracyte is high compared to other companies.

How does an increase in the price-earnings ratio of Veracyte affect the company?

An increase in the price-earnings ratio of Veracyte would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Veracyte affect the company?

A decrease in the price-earnings ratio of Veracyte would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Veracyte?

Some factors that influence the price-earnings ratio of Veracyte are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Veracyte pay?

Over the past 12 months, Veracyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Veracyte is expected to pay a dividend of 0 USD.

What is the dividend yield of Veracyte?

The current dividend yield of Veracyte is .

When does Veracyte pay dividends?

Veracyte pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Veracyte?

Veracyte paid dividends every year for the past 0 years.

What is the dividend of Veracyte?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Veracyte located?

Veracyte is assigned to the 'Health' sector.

Wann musste ich die Aktien von Veracyte kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Veracyte from 11/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/2/2024.

When did Veracyte pay the last dividend?

The last dividend was paid out on 11/2/2024.

What was the dividend of Veracyte in the year 2023?

In the year 2023, Veracyte distributed 0 USD as dividends.

In which currency does Veracyte pay out the dividend?

The dividends of Veracyte are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Veracyte stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Veracyte

Our stock analysis for Veracyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Veracyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.